AR095429A1 - Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis - Google Patents
Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosisInfo
- Publication number
- AR095429A1 AR095429A1 ARP140100973A ARP140100973A AR095429A1 AR 095429 A1 AR095429 A1 AR 095429A1 AR P140100973 A ARP140100973 A AR P140100973A AR P140100973 A ARP140100973 A AR P140100973A AR 095429 A1 AR095429 A1 AR 095429A1
- Authority
- AR
- Argentina
- Prior art keywords
- fibrosis
- alkenyl
- alkyl
- treatment
- aromatic compounds
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title abstract 2
- 230000004761 fibrosis Effects 0.000 title abstract 2
- 150000001491 aromatic compounds Chemical class 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 206010050207 Skin fibrosis Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 230000009787 cardiac fibrosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 201000002793 renal fibrosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
- C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
La presente se refiere a compuestos de fórmula (1) o una sal farmacéuticamente aceptable de este, en donde A es alquilo C₅, alquilo C₆, alquenilo C₅, alquenilo C₆, C(O)-(CH₂)ₙ-CH₃ o CH(OH)-(CH₂)ₙ-CH₃ en donde n es 3 ó 4; R¹ es H, F u OH; R² es alquilo C₅, alquilo C₆, alquenilo C₅, alquenilo C6, C(O)-(CH₂)ₙ-CH₃ o CH(OH)-(CH₂)ₙ-CH₃ en donde n es 3 ó 4; R³ es H, F, OH o CH₂Ph; R³ es H, F u OH; Q es i) (CH₂)ₘC(O)OH en donde m es 1 ó 2, ii) CH(CH₃)C(O)OH, iii) C(CH₃)₂C(O)OH, iv) CH(F)-C(O)OH, v) CF₂-C(O)OH o vi) C(O)-C(O)OH; y a composiciones que los contienen y el método de uso de estos para la prevención o el tratamiento de diversas enfermedades y afecciones fibróticas en los sujetos, incluida la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel, la fibrosis renal, la fibrosis del páncreas, la esclerosis sistémica, la fibrosis cardíaca o la degeneración macular.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798269P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095429A1 true AR095429A1 (es) | 2015-10-14 |
Family
ID=51535669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100973A AR095429A1 (es) | 2013-03-15 | 2014-03-13 | Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10023518B2 (es) |
| EP (1) | EP2970089B1 (es) |
| JP (1) | JP6448562B2 (es) |
| KR (1) | KR102196721B1 (es) |
| CN (2) | CN110105200B (es) |
| AR (1) | AR095429A1 (es) |
| AU (1) | AU2014231648B2 (es) |
| BR (1) | BR112015022008A2 (es) |
| CA (1) | CA2905621C (es) |
| CL (1) | CL2015002535A1 (es) |
| DK (1) | DK2970089T3 (es) |
| EA (1) | EA030651B1 (es) |
| ES (1) | ES2741439T3 (es) |
| HK (1) | HK1220440A1 (es) |
| IL (1) | IL241178B (es) |
| MX (1) | MX2015011878A (es) |
| MY (1) | MY180305A (es) |
| NZ (1) | NZ712797A (es) |
| PH (1) | PH12015502011A1 (es) |
| PL (1) | PL2970089T3 (es) |
| PT (1) | PT2970089T (es) |
| SG (1) | SG11201507408XA (es) |
| TW (1) | TWI689490B (es) |
| UY (1) | UY35402A (es) |
| WO (1) | WO2014138906A1 (es) |
| ZA (1) | ZA201507061B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| CA2897333C (en) | 2013-01-15 | 2021-07-06 | Incyte Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
| TWI689489B (zh) * | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| AU2014308703A1 (en) | 2013-08-23 | 2016-03-24 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| PL3203999T3 (pl) | 2014-10-10 | 2020-07-27 | Liminal Biosciences Limited | Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia osteoporozy |
| BR112017007420A2 (pt) * | 2014-10-10 | 2018-01-16 | Prometic Pharma Smt Limited | compostos aromáticos substituídos e composições farmacêuticas para impedir e tratar diabetes |
| RU2728782C2 (ru) | 2014-11-12 | 2020-07-31 | Лиминал Байосайенсиз Лимитед | Замещенные ароматические соединения и фармацевтические композиции для ауторепарации и регенерации ткани |
| JP6716598B2 (ja) * | 2015-03-18 | 2020-07-01 | ヴェクタス バイオシステムズ リミテッド | 腎臓及び／又は肝臓疾患を治療するための組成物 |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| JP7034914B2 (ja) * | 2015-11-23 | 2022-03-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体 |
| US10463645B2 (en) * | 2016-05-19 | 2019-11-05 | Everfront Biotech Inc. | Method for delaying the onset of pulmonary fibrosis or treating pulmonary fibrosis |
| TW201822805A (zh) | 2016-12-15 | 2018-07-01 | 深圳瑞健生命科學硏究院有限公司 | 一種預防和治療脂肪異常沉積導致的組織損傷的方法 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| KR102126389B1 (ko) * | 2018-09-14 | 2020-06-25 | 셀라이온바이오메드 주식회사 | 벤즈히드릴티오 아세트아미드 화합물을 유효성분으로 포함하는 간 질환의 예방 또는 치료용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020183519A1 (en) * | 2001-03-13 | 2002-12-05 | Herbert Nar | Antithrombotic carboxylic acid amides |
| JP2009538359A (ja) * | 2006-05-26 | 2009-11-05 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換カルボン酸化合物の製造および利用 |
| MX340993B (es) * | 2007-02-08 | 2016-08-02 | Emisphere Tech Inc * | Agentes de suministro de acido fenilalquilcarboxilico. |
| JP5844251B2 (ja) * | 2009-05-04 | 2016-01-13 | プロメティック・バイオサイエンシーズ・インコーポレイテッドＰｒｏＭｅｔｉｃ ＢｉｏＳｃｉｅｎｃｅｓ Ｉｎｃ． | ３−ペンチルフェニル酢酸の塩およびその薬学的使用 |
| KR101923354B1 (ko) * | 2009-05-04 | 2018-11-28 | 프로메틱 파마 에스엠티 리미티드 | 치환된 방향족 화합물 및 그의 약학적 용도 |
| AT509045B1 (de) * | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | Verbindungen zur behandlung von asthma bronchiale |
-
2014
- 2014-03-12 TW TW103108723A patent/TWI689490B/zh not_active IP Right Cessation
- 2014-03-13 UY UY0001035402A patent/UY35402A/es not_active Application Discontinuation
- 2014-03-13 AR ARP140100973A patent/AR095429A1/es unknown
- 2014-03-14 NZ NZ712797A patent/NZ712797A/en not_active IP Right Cessation
- 2014-03-14 PT PT14764458T patent/PT2970089T/pt unknown
- 2014-03-14 JP JP2015561849A patent/JP6448562B2/ja active Active
- 2014-03-14 WO PCT/CA2014/000236 patent/WO2014138906A1/en active Application Filing
- 2014-03-14 KR KR1020157029293A patent/KR102196721B1/ko active IP Right Grant
- 2014-03-14 AU AU2014231648A patent/AU2014231648B2/en not_active Ceased
- 2014-03-14 MY MYPI2015002293A patent/MY180305A/en unknown
- 2014-03-14 EA EA201591775A patent/EA030651B1/ru not_active IP Right Cessation
- 2014-03-14 SG SG11201507408XA patent/SG11201507408XA/en unknown
- 2014-03-14 EP EP14764458.7A patent/EP2970089B1/en active Active
- 2014-03-14 PL PL14764458T patent/PL2970089T3/pl unknown
- 2014-03-14 CN CN201910355464.7A patent/CN110105200B/zh not_active Expired - Fee Related
- 2014-03-14 CA CA2905621A patent/CA2905621C/en active Active
- 2014-03-14 US US14/776,328 patent/US10023518B2/en active Active
- 2014-03-14 ES ES14764458T patent/ES2741439T3/es active Active
- 2014-03-14 DK DK14764458.7T patent/DK2970089T3/da active
- 2014-03-14 MX MX2015011878A patent/MX2015011878A/es unknown
- 2014-03-14 CN CN201480013578.9A patent/CN105189438A/zh active Pending
- 2014-03-14 BR BR112015022008-8A patent/BR112015022008A2/pt active Search and Examination
-
2015
- 2015-09-03 IL IL241178A patent/IL241178B/en active IP Right Grant
- 2015-09-09 CL CL2015002535A patent/CL2015002535A1/es unknown
- 2015-09-09 PH PH12015502011A patent/PH12015502011A1/en unknown
- 2015-09-22 ZA ZA2015/07061A patent/ZA201507061B/en unknown
-
2016
- 2016-07-15 HK HK16108391.0A patent/HK1220440A1/zh unknown
-
2018
- 2018-04-04 US US15/945,408 patent/US10550066B2/en not_active Expired - Fee Related
-
2020
- 2020-02-03 US US16/780,316 patent/US11524930B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095429A1 (es) | Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis | |
| AR095427A1 (es) | Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca | |
| AR106141A1 (es) | Métodos e intermediarios para la preparación de derivados de ácidos biliares | |
| CL2020001090A1 (es) | Compuesto de pirimidina como inhibidor de las janocinasas. | |
| AR100244A1 (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| CO2022004594A2 (es) | Oxinitruro de piridina, método para su preparación y uso de este | |
| UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| AR094553A1 (es) | Formas de oxadiazolpirazina | |
| UY35288A (es) | Piridonamidas como moduladores de canales de sodio | |
| AR102361A1 (es) | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| AR085471A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona | |
| ECSP14004812A (es) | Triazolopiridinas sustituidas | |
| AR100006A1 (es) | Derivados de tubulisina | |
| AR101177A1 (es) | Inhibidores de la syk | |
| AR107828A1 (es) | 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k | |
| AR060647A1 (es) | Derivados de piperidina con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico, composiciones farmaceuticas que los comprenden, el uso de los mismos para la fabricacion de medicamentos para el tratamiento de afecciones pulmonares, metodos para preparar estos der | |
| PE20121523A1 (es) | Metodo de tratamiento | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR102246A1 (es) | Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis, usos | |
| AR101696A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| AR092861A1 (es) | Composiciones herbicidas que comprenden acido 4-amino-3-cloro-5-fluoro-6-(4-cloro-2-fluoro-3-metoxifenilo)piridina-2-carboxilico o un derivado del mismo y un sulfonilaminocarbonil triazolinona | |
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
| AR084883A1 (es) | Derivados de 2-metoxi-piridin-4-ilo | |
| AR054113A1 (es) | Forma cristalina solida de pantoprazol como acido libre, sales derivadas del mismo y proceso para su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |